Avoro Capital Advisors’s Relay Therapeutics RLAY Stock Holding History

Avoro Capital Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-400,000	Closed	-$8.95M	–	39
2022 Q3	$8.95M	Hold	400,000	–	–	0.17%	35
2022 Q2	$6.7M	Buy	+400,000	New	+$8.57M	0.13%	38
2021 Q2	–	Sell	-500,000	Closed	-$17.3M	–	49
2021 Q1	$17.3M	Hold	500,000	–	–	0.3%	37
2020 Q4	$20.8M	Hold	500,000	–	–	0.36%	31
2020 Q3	$21.3M	Buy	+500,000	New	+$19.1M	0.3%	34

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Avoro Capital Advisors's RLAY Position: Q4 2022 in Review

Avoro Capital Advisors sold out of Relay Therapeutics (RLAY) in Q4 2022, closing a stake of 400,000 shares — an estimated $8.95M sold.

Avoro Capital Advisors first reported a position in RLAY in Q3 2020 and held it in 5 quarters. The position peaked at $21.3M in Q3 2020. 165 funds tracked by Wall St. Rank hold RLAY as of Q4 2022.

Avoro Capital Advisors reported no remaining Relay Therapeutics position as of Q4 2022 after selling out during the quarter.
Avoro Capital Advisors sold 400,000 Relay Therapeutics shares in Q4 2022, an estimated $8.95M.
Avoro Capital Advisors first reported a position in Relay Therapeutics in Q3 2020 and held it in 5 quarters.
Avoro Capital Advisors's Relay Therapeutics position peaked at $21.3M in Q3 2020.
165 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2022.

Based on Avoro Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.